Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 14, 2010, Pages 2281-2290

  Moore, Keith A ^a   Callahan, Timothy S ^b   Maison Blanche, Pierre ^b   Morin, Isabelle ^c   Marenco, Ted ^c   Swearingen, Dennis ^c   Olbertz, Joy ^c  

^a Xanodyne Pharmaceuticals Inc   (United States)

^b Cardiodynamic Assessments   (United States)

^c CELERION   (United States)

Author keywords

ECG; Heavy menstrual bleeding; Pharmacodynamics; Pharmacokinetics; Thorough QTc trial; Tranexamic acid; Women

Indexed keywords

MOXIFLOXACIN; TRANEXAMIC ACID;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG RELEASE; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION; HEART RATE; HEART REPOLARIZATION; HOLTER MONITORING; HOSPITAL PATIENT; HUMAN; MENSTRUATION DISORDER; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTIFIBRINOLYTIC AGENTS; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MENORRHAGIA; MIDDLE AGED; QUINOLINES; TRANEXAMIC ACID;

EID: 77956583225     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.508071     Document Type: Article

References (28)

1. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundam Clin Pharmacol 2002;16:147-156
2. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022
3. Pratt CM, Hertz RP, Ellis BE, et al. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994;73:346-352
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022
5. Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 2005;28:115-125
6. Yang T, Snyders D, Roden DM. Drug block of I(Kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-744
7. United States Food and Drug Administration/Health Canada. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: Preliminary concept paper, 15 November 2002
8. International Conference on Harmonisation (ICH); Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, 7 February 2002
9. United States Food and Drug Administration, HHS. International Conference on Harmonisation; Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed Regist 2005;70:61134-61135
10. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981;20:65-72
11. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003;63:1417-1433
12. Pfizer Canada. Cyklokapron (tranexamic acid) package insert. Kirkland, Quebec; 2003
13. Mannucci PM. Drug therapy: hemostatic drugs. N Engl J Med 2003;339:245-253
14. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274-277
15. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995;102:401-406
16. Morganroth J, Ilson BE, Shaddinger BC. Evaluation of vardenafil and sildenafil on cardiac repoloriazation. Am J Cardiol 2004;93:1378-1383
17. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharm Ther 2008;84:475-480
18. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-1703
19. Morganroth J. A definite or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004;37:25-29
20. United States Food and Drug Administration, HHS. International Conference on Harmonisation; Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: Questions and answers, November 2008
21. Warmke JW, Ganetzky B. A family of potassium channel genes related to EAG in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-3442
22. Extramiana F, Maison-Blanche P, Badilini F, et al. Circadian modulation of QT rate dependence in healthy volunteers: gender and age differences. J Electrocardiol 1999;32:33-43
23. Toivonen L. More light of QT interval measurement. Heart 2002;87:193-194
24. Ahnve S, Vallin H. Influence of heart rate and inhibition of autonomic tone on the QT interval. Circulation 1982;65:435-439
25. Extramiana F, Maison-Blanche P, Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther 2005;77:247-258
26. Chen X, Cass JD, Bradley JA, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2005;146:792-799
27. Hnatkova K, Malik M. Optimum formulae for heart rate correction of the QT interval. Pacing Clin Electrophysiol 1999;22:1683-1687
28. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002;54:188-202